



165-⁷¹³306
5/9/03

PATENT
ATTORNEY DOCKET NO. 06727/008002

Certificate of Mailing: Date of Deposit: <u>April 30, 2003</u>	
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.	
<u>Susan M. Cannon</u> Printed name of person mailing correspondence	<u><i>Susan M. Cannon</i></u> Signature of person mailing correspondence

RECEIVED
MAY 07 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Stace Lindsay et al.	Art Unit:	1653
Serial No.:	10/030,351	Examiner:	Not Yet Assigned
Filed:	June 7, 2002	Customer No.:	21559
Title:	EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS		

Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the attached form PTO-1449, copies of which are enclosed. Also enclosed are copies of the International Search Report and European Search Report.

Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office Action on the merits.

Please apply any charges or credits to Deposit Account 03-2095.

Respectfully submitted,

Date:

April 30, 2003

Paul T. Clark


Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045
06727.008002 Supplemental IDS.doc



21559

PATENT TRADEMARK OFFICE



RECEIVED
MAY 07 2003
TECH CENTER 1600/2900

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 06727/008002		
				Serial No. 10/030,351		
				Applicant Stace Lindsay et al.		
				Filing Date June 7, 2002		
				Group 1653		
				IDS Filed April 30, 2003		
				Customer No. 21559		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 C.F.R. § 1.98(b))						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,766,884	06/16/98	Townes et al.			
	5,831,141	11/03/98	Lubon et al.			
	5,843,776	12/01/98	Tamaoki et al.			
	6,013,857	01/11/00	Deboer et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 95/00637	01/05/95	W.I.P.O.			
	WO 96/09377	03/28/96	W.I.P.O.			
	WO 96/22787	08/01/96	W.I.P.O.			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Bennett et al., "Similarity Between Natural and Recombinant Human Alpha-Fetoprotein as Inhibitors of Estrogen-Dependent Breast Cancer Growth," Breast Cancer Research and Treatment 45:169-179 (1997).					
	Birrer et al., "The Immunology of Alphafetoprotein," Journal of Tumor Marker Oncology 14:55-62 (1999), (Abstract).					
	Dudich et al., "Growth-Regulative Activity of Human Alpha-Fetoprotein for Different Types of Tumor and Normal Cells," Tumor Biology 19:30-40 (1998).					
	Koyama et al., "Lectin Affinity Electrophoretic Demonstration of Tissue Specificity and Malignant Alteration of Human α -Fetoprotein Isoforms Produced in Transgenic Mice," Biochemical and Biophysical Research Communications 223:757-761 (1996).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						